首页> 美国卫生研究院文献>Stem Cells International >Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence
【2h】

Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence

机译:间充质干细胞为基础的肾脏疾病治疗:临床证据的审查。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mesenchymal stem cells form a population of self-renewing, multipotent cells that can be isolated from several tissues. Multiple preclinical studies have demonstrated that the administration of exogenous MSC could prevent renal injury and could promote renal recovery through a series of complex mechanisms, in particular via immunomodulation of the immune system and release of paracrine factors and microvesicles. Due to their therapeutic potentials, MSC are being evaluated as a possible player in treatment of human kidney disease, and an increasing number of clinical trials to assess the safety, feasibility, and efficacy of MSC-based therapy in various kidney diseases have been proposed. In the present review, we will summarize the current knowledge on MSC infusion to treat acute kidney injury, chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, systemic lupus erythematosus, and kidney transplantation. The data obtained from these clinical trials will provide further insight into safety, feasibility, and efficacy of MSC-based therapy in renal pathologies and allow the design of consensus protocol for clinical purpose.
机译:间充质干细胞形成可自我更新的多能细胞,可以从几种组织中分离出来。多项临床前研究表明,外源性MSC的给药可以通过一系列复杂的机制,特别是通过免疫系统的免疫调节以及旁分泌因子和微泡的释放,来预防肾脏损伤并促进肾脏恢复。由于其治疗潜力,MSC被评估为治疗人类肾脏疾病的可能参与者,并且提出了越来越多的临床试验以评估基于MSC的疗法在各种肾脏疾病中的安全性,可行性和有效性。在本综述中,我们将总结有关MSC输注以治疗急性肾损伤,慢性肾脏疾病,糖尿病性肾病,局灶性节段性肾小球硬化,系统性红斑狼疮和肾脏移植的最新知识。从这些临床试验中获得的数据将提供对基于MSC的疗法在肾脏病理中的安全性,可行性和功效的进一步了解,并允许设计用于临床目的的共识方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号